What is the best medicine for PDA?

Treating PDA in Newborns: Medication Options

Patent ductus arteriosus (PDA) is a common condition in premature infants, where the ductus arteriosus—normally a temporary blood vessel in fetal circulation—fails to close after birth. This can lead to complications such as heart failure and respiratory distress, especially in low-birth-weight babies. Prompt treatment is often necessary to support the infant’s development and stabilize their condition.

The preferred medical treatment for PDA involves the use of nonsteroidal anti-inflammatory drugs (NSAIDs), specifically intravenous indomethacin or ibuprofen. These medications work by promoting closure of the ductus arteriosus through inhibition of prostaglandin synthesis, which plays a key role in keeping the vessel open during fetal life.

Among the two, IV ibuprofen has become a widely used alternative to indomethacin, especially due to a potentially more favorable side effect profile in some neonates. The standard dosing regimen for ibuprofen is a loading dose of 10 mg/kg given as an IV bolus, followed by 5 mg/kg per day in divided doses for two additional days. This approach has shown high success rates in closing the PDA while minimizing renal and gastrointestinal risks.

While both medications are effective, the choice often depends on the infant's clinical status, gestational age, kidney function, and institutional protocols. In cases where drug therapy fails, surgical or transcatheter closure remains an option.

It’s important to note that not all PDAs require treatment—small, hemodynamically insignificant ducts may close on their own. However, in symptomatic or high-risk infants, timely pharmacologic intervention can make a significant difference in outcomes. Decisions are always made carefully by neonatal care teams to balance benefits and potential complications.